tapebrief
ABT · Q1 2026

ABT · Q2 2026 Earnings

Cautious

Abbott Laboratories

Reported July 16, 2026

30-second summary

30-second take: Abbott posted Q2 FY2026 revenue of $12.59B (+13.0% reported, +4.8% comparable, +0.6% above consensus $12.52B) and adjusted EPS of $1.31 (+2.3% above consensus $1.28), landing at the high end of the prior $1.25–$1.31 guide. Management raised FY2026 adjusted EPS to $5.45–$5.60 (midpoint $5.525, up $0.045 from prior $5.48) while reaffirming the 6.5–7.5% comparable sales growth guide — a stance that still requires meaningful H2 acceleration after Q2 comparable growth of only 4.8%. Devices (+8.4% comparable) and Established Pharma (+8.7% comparable) continue to carry; Cancer Diagnostics (Exact Sciences) grew 13.3% comparable in its first full-quarter contribution, and CGM comparable growth of 9.5% came in just below the "return to double-digit" commitment.

Headline numbers

EPS

Q2 FY2026

$1.31

+2.3% vs est.

Revenue

Q2 FY2026

$12.59B

+4.8% YoY

+0.6% vs est.

Gross margin

Q2 FY2026

52.5%

Operating margin

Q2 FY2026

13.4%

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$12.59B$11.14B+13.0%$11.16B+12.8%
EPS$1.31$1.26+4.0%$1.15+13.9%
Gross margin52.5%52.7%-20bps52.4%+10bps
Operating margin13.4%18.4%-500bps12.0%+140bps

Guidance

Abbott raised full-year 2026 EPS guidance to $5.45–$5.60 (from $5.38–$5.58) driven by strong Q2 beat and confidence in H2 acceleration, while reaffirming comparable sales growth and introducing Q3 EPS guidance of $1.38–$1.46.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted diluted EPSQ2 FY2026$1.25 to $1.31$1.31+0.00 at high end of guideBeat

New guidance

MetricPeriodGuideYoY
Adjusted diluted EPSQ3 FY2026$1.38 to $1.46+8-14% YoY

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted diluted EPS
FY2026
$5.38 to $5.58$5.45 to $5.60Midpoint +0.045 (+0.8%); low end +0.07; high end +0.02Raised

Reaffirmed unchanged this quarter: Comparable sales growth (6.5% to 7.5%)

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Nutrition$2.144B$2.212B-3.1%
Diagnostics$3.092B$2.173B+42.3%
Cancer Diagnostics$0.919B—+13.3%
Established Pharmaceuticals$1.499B$1.383B+8.4%
Medical Devices$5.853B$5.369B+9.0%
Electrophysiology$0.861B$0.7B+23.0%
Diabetes Care$2.188B$1.981B+10.4%
Core Laboratory Diagnostics growth3.2% comparable——
Rhythm Management growth9.5% comparable——
Heart Failure growth8.7% comparable——

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
U.S.$5.216B—+3.5%
International$7.377B—+5.8%
Cologuard growthmid-teens growth——
Continuous glucose monitor sales growth9.5% comparable——
Shareholder returns (Q2 2026)$2.1 billion——
Dividend per share$0.63——
Consecutive years of dividend increases54 years——

Management tone

No earnings call transcript was available for this quarter; the following observations are drawn from the press release only.

Narrative arc: Q3 FY2025 cautious execution → Q4 FY2025 nutrition reset → Q1 FY2026 visibility-dependent acceleration → Q2 FY2026 EPS raise on H2 conviction.

The press release doubles down on the H2 acceleration framing that has been the central story since Q1: "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year." The phrase is nearly identical to the Q1 framing of "clear visibility to the key drivers of that acceleration." What has changed is the willingness to raise the EPS midpoint — modestly, $0.045 — which is management's first concrete "put a chip down" moment on the H2 story. The comparable sales guide, however, was reaffirmed rather than raised, which is the tell: management is confident in the EPS bridge (mix, margin, share repurchase, Exact Sciences accretion) but is not yet willing to underwrite the top-line acceleration with a lifted range. That asymmetry — raise EPS, hold sales — is the quiet signal that H2 revenue delivery still carries execution risk.

Answers to last quarter's watch list

Q2 FY2026 comparable sales growth print vs. ~7% implied — Q2 comparable sales growth was 4.8% (directly disclosed). This is below the 5.5% "arithmetically defensible" threshold and well below the 6.5–7.5% FY guide midpoint.
Resolved negatively
CGM comparable growth — does it actually return to double digits? — CGM comparable growth printed at 9.5% — just below the 10% threshold flagged. Reported growth (+11.0%) benefits from FX. Management committed last quarter to a "return to double-digit" in Q2; the 9.5% miss is small but the commitment was not cleanly met. Status: Resolved negatively (marginally)
Nutrition Q2 comparable YoY — Nutrition declined 3.6% comparable in Q2, narrowing further from Q1's -6.0% and Q4 FY2025's -8.9%. This is the cleanest evidence yet that the pricing/promotion pivot is working. The trajectory supports the H2 recovery thesis for this specific segment.
Resolved positively
Ex-Exact Sciences organic disclosure — The press release provides comparable growth rates by segment but does not explicitly quantify the ex-Exact Sciences organic rate for the total company. Cancer Diagnostics is disclosed as a distinct sub-segment ($919M, +13.3% comparable), which does allow a rough back-out, but management has not committed to a clean ex-Exact disclosure framework.
Not resolved
Exact Sciences contribution disclosure — Cancer Diagnostics disclosed as a distinct sub-segment with $919M revenue and +13.3% comparable growth in Q2. First full-quarter contribution shows the acquired asset is performing at the top of the mid-teens growth range management guided.
Resolved positively
Structural Heart U.S. comparable — Structural Heart U.S. comparable declined 0.9% in Q2 (reported -9.8%, distorted by the multi-year competitor payment prior-year comp). Total Medical Devices grew 8.4% comparable. The U.S. Structural Heart comparable trajectory bending back toward Ford's high-single-digit FY commitment is not yet visible in the print.
Continue monitoring
Electrophysiology growth rate as Volt scales — EP grew 14.0% reported / 13.4% comparable in Q2, clearing the 13% "PFA competitive dynamic" watermark on both bases.
Resolved positively

What to watch into next quarter

Q3 FY2026 comparable sales growth vs. FY guide — With Q2 comparable at 4.8% and segment comparable growth mostly in the 3–10% band, Q3 needs to show a step-up toward at least 6.5% comparable growth for the FY guide to remain arithmetically credible. Anything sub-6% in Q3 would force a Q4 miracle to hold the range.

CGM comparable growth — does it clear 10%? — Q2 came in at 9.5% comparable, just short of the double-digit commitment. Q3 needs to print above 10% comparable to reset the "structural CGM growth" narrative; another sub-10% quarter would confirm the deceleration is structural, not tender-related.

Nutrition — does the narrowing continue? — Trajectory is -8.9% → -6.0% → -3.6% comparable over three quarters. Q3 needs to break above -2% or reach flat/positive to validate the H2 recovery thesis on schedule. A stall around -3% to -4% would signal the fix is running out of momentum.

Q3 EPS landing within $1.38–$1.46 — Implied FY2026 remainder EPS of $2.79 (from midpoint $5.525 less H1 $2.46) requires H2 EPS to accelerate. Q3 EPS at or above $1.42 midpoint would validate the FY raise; below $1.38 would force another FY revision.

Ex-Exact Sciences organic quantification — Management has now had two quarters to disclose the ex-Exact organic rate cleanly. Continued reliance on comparable-basis framing (which flatters underlying trends) would itself be a signal about the true underlying momentum.

Operating margin trajectory — Q2 GAAP operating margin was 13.4% in the press release; the FY 50–70bps expansion commitment requires adjusted operating margin leverage to materialize in H2. Watch Q3 adjusted operating margin disclosure for confirmation the leverage is arriving.

Sources

  1. Abbott Laboratories Q2 FY2026 Earnings Press Release, Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-2026q2xexhibitx991.htm
  2. Tapebrief Q1 FY2026 ABT brief (for prior guidance baseline and watch-list context)
  3. Tapebrief Q4 FY2025 ABT brief (for multi-quarter tone arc and nutrition trajectory)
  4. Tapebrief Q3 FY2025 ABT brief (for narrative arc anchor)
  5. Tapebrief Q2 FY2025 ABT brief (for narrative arc anchor)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.